News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Study of GlaxoSmithKline Platelet Drug, Promacta Halted Due to Clots
May 13, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- U.S. regulators said on Wednesday a study among liver-disease patients taking GlaxoSmithKline's (GSK.L)(GSK.N) Promacta treatment for low blood platelets was halted due to blood-clot safety issues.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
GlaxoSmithKline
MORE ON THIS TOPIC
Immunology and inflammation
Nektar Provides More Data for Dermatitis Drug, but Key Questions Remain Unanswered
September 19, 2025
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Roivant, Pfizer’s Therapy Shows ‘Patient-Centered Benefit’ in Rare Inflammatory Condition
September 18, 2025
·
2 min read
·
Tristan Manalac
Pain
Lexicon Backs Phase III Go Decision for Non-Opioid Pain Med With Post-Hoc Analysis
September 18, 2025
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Deep Dive: Oral Obesity Drugs on the Cusp
September 18, 2025
·
3 min read
·
Heather McKenzie
